Hepatic stellate cells: a target for the treatment of liver fibrosis
- PMID: 11023037
- DOI: 10.1007/s005350070045
Hepatic stellate cells: a target for the treatment of liver fibrosis
Abstract
Hepatic fibrosis is a wound-healing process that occurs when the liver is injured chronically. Hepatic stellate cells (HSC) are responsible for the excess production of extracellular matrix (ECM) components. The activation of HSC, a key issue in the pathogenesis of hepatic fibrosis, is mediated by various cytokines and reactive oxygen species released from the damaged hepatocytes and activated Kupffer cells. Therefore, inhibition of HSC activation and its related subsequent events, such as increased production of ECM components and enhanced proliferation, are crucial goals for intervention in the hepatic fibrogenesis cascade. This is especially true when the etiology is unknown or there is no established therapy for the cause of the chronic injury. This review explores the rationale for choosing HSC as a target for the pharmacological, molecular, and other novel therapeutics for hepatic fibrosis. One focus of this review is the inhibition of two cytokines, transforming growth factor-beta and platelet-derived growth factor, which are important in hepatic fibrogenesis. A number of new agents, such as Chinese herbal recipes and herbal extracts, silymarin, S-adenosyl-L-methionine, polyenylphosphatidylcholine, and pentoxifylline are also discussed.
Similar articles
-
[Hepatic stellate cells and oxidative stress].Rev Esp Enferm Dig. 2007 Apr;99(4):223-30. doi: 10.4321/s1130-01082007000400007. Rev Esp Enferm Dig. 2007. PMID: 17590105 Review. Spanish.
-
Molecular therapy for hepatic injury and fibrosis: where are we?World J Gastroenterol. 2006 Jan 28;12(4):509-15. doi: 10.3748/wjg.v12.i4.509. World J Gastroenterol. 2006. PMID: 16489661 Free PMC article. Review.
-
[Hepatic fibrogenesis].Korean J Gastroenterol. 2006 Nov;48(5):297-305. Korean J Gastroenterol. 2006. PMID: 17132917 Korean.
-
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.Sci Rep. 2016 Sep 16;6:33453. doi: 10.1038/srep33453. Sci Rep. 2016. PMID: 27634375 Free PMC article.
-
Ligustrazine attenuates oxidative stress-induced activation of hepatic stellate cells by interrupting platelet-derived growth factor-β receptor-mediated ERK and p38 pathways.Toxicol Appl Pharmacol. 2012 Nov 15;265(1):51-60. doi: 10.1016/j.taap.2012.09.016. Epub 2012 Sep 27. Toxicol Appl Pharmacol. 2012. PMID: 23022513
Cited by
-
Cloning and promoter activity of rat Smad1 5'-flanking region in rat hepatic stellate cells.Mol Cell Biochem. 2007 Oct;304(1-2):227-34. doi: 10.1007/s11010-007-9504-8. Epub 2007 May 26. Mol Cell Biochem. 2007. PMID: 17530186
-
The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model.Biomed Res Int. 2019 Jun 2;2019:9846919. doi: 10.1155/2019/9846919. eCollection 2019. Biomed Res Int. 2019. PMID: 31275996 Free PMC article.
-
Gentiopicroside Ameliorates the Progression from Hepatic Steatosis to Fibrosis Induced by Chronic Alcohol Intake.Biomol Ther (Seoul). 2020 Jul 1;28(4):320-327. doi: 10.4062/biomolther.2020.008. Biomol Ther (Seoul). 2020. PMID: 32248671 Free PMC article.
-
Oligonol Ameliorates CCl₄-Induced Liver Injury in Rats via the NF-Kappa B and MAPK Signaling Pathways.Oxid Med Cell Longev. 2016;2016:3935841. doi: 10.1155/2016/3935841. Epub 2015 Dec 21. Oxid Med Cell Longev. 2016. PMID: 26798422 Free PMC article.
-
Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis.J Transl Med. 2012 Apr 25;10:75. doi: 10.1186/1479-5876-10-75. J Transl Med. 2012. PMID: 22533821 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
